SLS
Sellas Life Sciences Group Inc
NASDAQ: SLS · HEALTHCARE · BIOTECHNOLOGY
$5.25
+10.38% today
Updated 2026-06-04
Market cap
$1.52B
P/E ratio
—
P/S ratio
26.90x
EPS (TTM)
$-0.23
Dividend yield
—
52W range
$1 – $10
Volume
7.6M
WallStSmart proprietary scores
17
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D7.3
Quality
B+3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$10.00
+90.48%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-8.85M
- Revenue declining -82.50% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $1.00M | $0.00 | $0.00 | $0.00 | $0.00 | $0.0B |
| Net income | $-41.30M | $-37.34M | $-30.88M | $-26.86M | $-8.41M | — |
| EPS | — | — | — | — | $-0.23 | $-0.20 |
| Free cash flow | $-28.31M | $-36.91M | $-35.40M | $-28.39M | $-8.85M | — |
| Profit margin | -4,130.10% | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-01-07 | WASMAN, JANE | Buy | 50,000 | — |
| 2026-01-07 | VARIAN, JOHN | Buy | 50,000 | — |
| 2026-01-07 | VAN, NOSTRAND ROBERT L | Buy | 50,000 | — |
Peer comparison
Smart narrative
Sellas Life Sciences Group Inc trades at $5.25. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score.
Frequently asked questions
What is Sellas Life Sciences Group Inc's stock price?
Sellas Life Sciences Group Inc (SLS) trades at $5.25, on a P/S of 26.9x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Sellas Life Sciences Group Inc overvalued?
Sellas Life Sciences Group Inc carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Sellas Life Sciences Group Inc (SLS)?
The 12-month analyst consensus target is $10.00, about 90.5% above the current $5.25. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of SLS by 2030?
Our research-backed model puts the 2030 base case at $8.92, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio26.90x
ROE-43.60%
Beta2.53
50D MA$6.11
200D MA$3.72
Shares out0.20B
Float0.19B
Short ratio—
Avg volume7.6M
Performance
1 week-13.27%
1 month+59.43%
3 months+70.99%
YTD+106.37%
1 year—
3 years—
5 years—